Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

By J. Chiasson, R. Josse, R. Gomis, M. Hanefeld, A. Karasik, Markku Laakso, Theodora S Temelkova-Kurktschiev. The Lancet, 2002

2,532 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. (2004, result): “The recent results of the STOP-NIDDM trial also point to its use for delaying the development of type 2 diabetes in patients with impaired glucose tolerance (IGT).(17) Acarbose reduces HbA1c and postprandial insulin levels, improves insulin sensitivity and is not associated with weight gain.”
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) (2006, background): “Pharmacological agents such as metformin [1], troglitazone [5, 6] and acarbose [7] have also been found to be effective.”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Both medications are relatively well-tolerated and safe, and they may confer a cardiovascular risk benefit (63-66).”
Follow-up report on the diagnosis of diabetes mellitus. (2003, background): “Finally, data from major clinical trials that tested whether the progression from IGT to diabetes could be delayed or prevented by a treatment intervention have produced concordant results: intensive lifestyle modification (nutritional and exercise interventions) (18,19), metformin (19,20), and acar”